Dae Gon Ha
Stock Analyst at Stifel
(1.70)
# 3,003
Out of 4,828 analysts
48
Total ratings
33.33%
Success rate
-0.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.45 | +106.90% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $76.76 | -3.60% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $5.36 | -44.03% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $1.15 | +1,291.30% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $8.12 | +688.18% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $132.18 | +66.44% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $44.33 | +48.88% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $35.11 | +261.72% | 2 | May 31, 2024 | |
| ABEO Abeona Therapeutics | Initiates: Buy | $21 | $5.27 | +298.48% | 1 | May 30, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $4.23 | +845.63% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $6.99 | +586.70% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.30 | +1,289.96% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.39 | +1,678.91% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $57.36 | -56.42% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $6.00 | +166.89% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $8.50 | +3,252.94% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.61 | +1,146.11% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.45 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $17.31 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.97 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.61 | +645.34% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $9.80 | +4,900.00% | 2 | Oct 23, 2017 |
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.45
Upside: +106.90%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $76.76
Upside: -3.60%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $5.36
Upside: -44.03%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $1.15
Upside: +1,291.30%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $8.12
Upside: +688.18%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $132.18
Upside: +66.44%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $44.33
Upside: +48.88%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $35.11
Upside: +261.72%
Abeona Therapeutics
May 30, 2024
Initiates: Buy
Price Target: $21
Current: $5.27
Upside: +298.48%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $4.23
Upside: +845.63%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $6.99
Upside: +586.70%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $1.30
Upside: +1,289.96%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.39
Upside: +1,678.91%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $57.36
Upside: -56.42%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $6.00
Upside: +166.89%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $8.50
Upside: +3,252.94%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.61
Upside: +1,146.11%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.45
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $17.31
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $9.97
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $1.61
Upside: +645.34%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $9.80
Upside: +4,900.00%